SP1 and osteosarcoma: Although we showed an HDAC–SP1–TOP2A regulation axis in osteosarcoma, other HDAC and/or SP1 downstream pathways/targets beyond TOP2A may also contribute to the supra‐additive effect of HDAC inhibitors and DOX in osteosarcoma.